Anti-UBC9/UBE2I Antibody, clone 2H5 ZooMAb^® Rabbit Monoclonal

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 2H5 is a ZooMAb^® Rabbit recombinant monoclonal antibody that specifically detect UBC9/UBE2I.

His-tagged recombinant fragment corresponding to 145 amino acids ( aa 2-146) of human UBC9.

Quality Control Testing

Evaluated by Western Blotting in Jurkat cell lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected UBC9/UBE2I in Jurkat cell lysate.

Tested Applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected UBC9/UBE2I in U251 MG, NIH3T3, and COS-7 cell lysates.

Immunohistochemistry (Paraffin) Analysis: A 1:1,000 dilution from a representative lot detected UBC9/UBE2I in human fallopian tube tissue sections.

Affinity Binding Assay: A representative lot of this antibody bound UBC9/UBE2I recombinant fragment with a KD of 4.0 x 10-8 in an affinity binding assay.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected UBC9/UBE2I in Jurkat cells.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

SUMO-conjugating enzyme UBC9 (UniProt: P63279; also known as RING-type E3 SUMO transferase UBC9, SUMO-protein ligase, Ubiquitin carrier protein 9, Ubiquitin carrier protein I, Ubiquitin-conjugating enzyme E2 I) is encoded by the UBE2I (also known as UBC9, UBCE9) gene (Gene ID: 7329) in human. SUMOylation is process that adds a small ubiquitin-like modifier (SUMO) polypeptide to the -amino group of a lysine residue of proteins. UBC9 is a SUMO-conjugating enzyme 2 ligase that is expressed in multiple tissues, including heart, skeletal muscle, pancreas, kidney, liver, lung, placenta, brain, testis, and thymus. It accepts SUMO1, SUMO2, SUMO3, SUMO4 and SUMO1P1/SUMO5 from the UBLE1A-UBLE1B E1 complex and catalyzes their covalent attachment to other proteins with the help of an E3 ligase. It can catalyze the formation of poly-SUMO chains. Its UBC domain is localized in amino acids 4-157. It is reported to sumoylate p53/TP53 at lysine 386. Its expression is shown to increase during reprogramming of mouse embryonic fibroblasts (MEFs) into induced pluripotent stem (iPS) cells and its suppression inhibits iPS cell induction. Knockdown of UBC9 is reported to decreases the expression of Nanog, Klf4, Oct4, and Sox2 in embryonic stem cells. UBC9 also has a cardioprotective role and is shown to improve cardiac function and ease left ventricle remodeling following myocardial infarction. Phosphorylation of serine 71 of UBC9 enhances its SUMOylation activity. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Xiao, Q., et al. (2020). Front. Pharmacol. 11; 561306; Tahmasebi, S., et al. (2014). Stem Cells. 32(4); 1012-1020; Gupta, MK., et al. (2014). Cir. Res. 115(8); 721-729).

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

0.3 mg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.